Skip to main content
Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR14

Effect of Clinically Embedded Pharmacists on the Time of Other Oncology Clinicians

JHOP - March 2025 Vol 15 Special Feature - HOPA Abstracts
Maja Hill, PharmD; Emily Mackler, PharmD, BCOP; Maisa Nazzal, PharmD, MS; Karen Farris, PhD; Emily Johengen, PharmD, BCACP; Katie Sias, PharmD, BCOP, et al.

Presenting Authors: Maja Hill, PharmD, Lemon-Holton Cancer Pavilion, Corewell Health, Grand Rapids, MI; and Emily Mackler, PharmD, BCOP, Michigan Oncology Quality Consortium, Michigan Institute for Care Management and Transformation, YesRx, and University of Michigan College of Pharmacy, Ann Arbor, MI

Co-Authors: Maisa Nazzal, PharmD, MS, and Karen Farris, PhD, University of Michigan College of Pharmacy, Ann Arbor, MI; Emily Johengen, PharmD, BCACP, Trinity Health IHA Hematology Oncology, Ypsilanti, MI; Katie Sias, PharmD, BCOP, Pardee Cancer Wellness Center, MyMichigan Health, Midland, MI; Samuel Snowaert, PharmD, BCOP, MBA, Covenant Cancer Care Center, Saginaw, MI; Jennifer VanSickler, PharmD, Herbert-Herman Cancer Center, University of Michigan Health-Sparrow, Lansing, MI; Mark Wagner, PharmD, BCOP, and Colton Zwart, PharmD, BCOP, Cowell Family Cancer Center, Munson Healthcare, Traverse City, MI; Katie Young and David Reyes-Gastelum, Michigan Institute for Care Management and Transformation, Ann Arbor, MI

BACKGROUND: Clinical pharmacists save physicians’ time through interventions and clinical services offered in the emergency department, but studies evaluating time savings in oncology practice have not been done.1 Clinical pharmacists embedded in ambulatory care practices provide a variety of services, such as selecting appropriate chemotherapy regimens and supportive care, reviewing medication lists and laboratory tests, managing adverse events, educating patients, and answering drug information questions. Administratively, they may also build order sets, provide staff education, and release orders. The purpose of this study was to describe the time spent by embedded clinical oncology pharmacists and whom that effort would be attributed to if they were not in the clinic.

METHODS: On 2 different weeks, 7 pharmacists from Pharmacists Optimizing Oncology Care Excellence in Michigan practices recorded their activities using a data collection form that included patient- and non–patient-focused activities.2 The second data collection is the basis for this analysis, and data were collected in July 2024. The 7 pharmacists provided 922 entries grouped into administration, chart review/release orders, care coordination, clinical question, documentation, follow-up, order management, teach, staff education, and other. The number of minutes attributed to the activity and the professional who would do the activity if the clinical pharmacist was not present were recorded. Hours per activity and the substituted professional were determined.

RESULTS: Pharmacists recorded activities for an average of 42 hours per week, and 70% of activities were patient- focused. Among patient-focused activities, pharmacists’ distribution of time was primarily focused on chart reviewing and releasing orders, teaching, and documentation. For patient-focused activities, pharmacists substituted a mean of 5 hours for advance practice practitioners, 3.3 hours for physicians, 1 hour for medical assistants, 11.8 hours for nurses, 4.1 hours for another pharmacist, and 3.7 hours for no one in the clinic on a per-pharmacist-per-week basis. For non–patient-focused activities, the clinical pharmacists substituted 7.3 hours for no one in the clinic and 4.1 hours for another pharmacist, per pharmacist per week.

CONCLUSION: Oncology pharmacists’ time was 70% patient-focused, and they saved on average 20 hours per week per pharmacist for nurses, advance practice practitioners, and physicians.

  1. Grill J, Bryant C, Markel K, Wisniewski SJ. A study of time saved by emergency medicine physicians through working with clinical pharmacists in the emergency department. Am J Emerg Med. 2019;37:1720-1722.
  2. POEM program. Accessed October 4, 2024. www.moqc.org/poem
Related Items
Evaluation of a Biosimilar Conversion in an Academic Medical Center Outpatient Infusion Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Outcomes of Supportive Care Versus Pharmacologic Intervention for the Management of CRS in Relapsed or Refractory Multiple Myeloma Treated With BCMA- and GPRC5D-Directed Bispecifics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
From Diagnosis to Decision-Making: Black Patient and Caregiver Perspectives on Lung Cancer Care and Support Needs
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Safety of Live-Attenuated MMR Vaccination in Patients With Multiple Myeloma Receiving Daratumumab After Autologous Stem-Cell Transplantation
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
A Real-World Analysis of Filgrastim and Biosimilars for Engraftment After Hemopoietic Cell Transplantation: Balancing Efficacy and Economics
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Impact of an Oncolytic Pharmacist Prescription Verification Queue at an Academic Medical Center
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Talquetamab-Induced Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma: A Multicenter, Retrospective Study
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Phase 3 Study to Evaluate Efficacy and Safety of Pemivibart, an IgG1 Monoclonal Antibody, for the Prevention of COVID-19 (CANOPY): Subset Analysis of Participants With Chronic Lymphocytic Leukemia
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Safety of Shortened Postinfusion Observation Times for Pertuzumab and Ado-trastuzumab Emtansine: Retrospective and Prospective Analyses
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts
Real-World Incidence of Infusion-Related Reactions With Sacituzumab Govitecan and Opportunities for Premedication De-Escalation
JHOP - March 2026 Vol 16 Special Feature published on March 3, 2026 in HOPA Abstracts